Minnai Francesca, Noci Sara, Esposito Martina, Schneider Marc A, Kobinger Sonja, Eichhorn Martin, Winter Hauke, Hoffmann Hans, Kriegsmann Mark, Incarbone Matteo A, Mattioni Giovanni, Tosi Davide, Muley Thomas, Dragani Tommaso A, Colombo Francesca
Institute for Biomedical Technologies, National Research Council, Segrate, 20054 Milan, Italy.
Department of Medical Biotechnology and Translational Medicine (BioMeTra), Università degli Studi di Milano, 20122 Milan, Italy.
Cancers (Basel). 2024 Sep 25;16(19):3264. doi: 10.3390/cancers16193264.
BACKGROUND/OBJECTIVES: Lung cancer remains a global health concern, with substantial variation in patient survival. Despite advances in detection and treatment, the genetic basis for the divergent outcomes is not understood. We investigated germline polymorphisms that modulate overall survival in 1464 surgically resected lung adenocarcinoma patients.
A multivariable Cox proportional hazard model was used to assess the association of more than seven million polymorphisms with overall survival at the 60-month follow-up, considering age, sex, pathological stage, decade of surgery and principal components as covariates. Genes in which variants were identified were studied in silico to investigate functional roles.
Six germline variants passed the genome-wide significance threshold. These single nucleotide polymorphisms were mapped to non-coding (intronic) regions on chromosomes 2, 3, and 5. The minor alleles of rs13000315, rs151212827, and rs190923216 (chr. 2, 3 and 5, respectively) were found to be independent negative prognostic factors. All six variants have been reported to regulate the expression of nine genes, seven of which are protein-coding, in different tissues. Survival-associated variants on chromosomes 2 and 3 were already reported to regulate the expression of and , with high expression associated with the minor alleles. High and expression in lung adenocarcinoma tissue was already shown to correlate with poor overall survival.
This study highlights a potential regulatory role of the identified polymorphisms in influencing outcome and suggests a mechanistic link between these variants, gene expression regulation, and lung adenocarcinoma prognosis. Validation and functional studies are warranted to elucidate the mechanisms underlying these associations.
背景/目的:肺癌仍然是一个全球健康问题,患者生存率存在很大差异。尽管在检测和治疗方面取得了进展,但对于不同预后的遗传基础仍不清楚。我们研究了1464例接受手术切除的肺腺癌患者中调节总生存期的种系多态性。
使用多变量Cox比例风险模型评估超过700万个多态性与60个月随访时总生存期的关联,将年龄、性别、病理分期、手术年代和主成分作为协变量。对鉴定出变异的基因进行计算机模拟研究以探究其功能作用。
六个种系变异通过了全基因组显著性阈值。这些单核苷酸多态性定位于2号、3号和5号染色体上的非编码(内含子)区域。发现rs13000315、rs151212827和rs190923216(分别位于2号、3号和5号染色体)的次要等位基因是独立的负性预后因素。据报道,所有六个变异在不同组织中调节九个基因的表达,其中七个是蛋白质编码基因。2号和3号染色体上与生存相关的变异已被报道调节 和 的表达,高表达与次要等位基因相关。肺腺癌组织中高 和 表达已被证明与较差的总生存期相关。
本研究强调了所鉴定的多态性在影响预后方面的潜在调节作用,并提示这些变异、基因表达调控与肺腺癌预后之间存在机制联系。有必要进行验证和功能研究以阐明这些关联背后的机制。